Trending — Top Pharma Rep Posts

Most upvoted anonymous posts from pharmaceutical sales representatives.

• Is it ever the right time to leave big pharma for a smaller biotech? — Pfizer · 88 upvotes
• B&L NSM 2026 quota setting — did anyone else leave feeling scammed? — Bausch Health · 67 upvotes
• Novartis routing PTO claims through MetLife now — anyone else hit delays? — Novartis · 61 upvotes
• J&J remapping whole territories March 31 — anyone affected? — Johnson & Johnson (Janssen) · 52 upvotes
• Novo pod restructuring wiping out whole districts — anyone else get the call? — Novo Nordisk · 47 upvotes
• Alnylam comp and culture — honest 2-year review — Alnylam Pharmaceuticals · 45 upvotes
• Opdivo + Yervoy combo — competitive update from the field — Bristol Myers Squibb · 44 upvotes
• Amgen post-Horizon integration still a mess — Tepezza access getting worse — Amgen · 43 upvotes
• Lilly GLP-1 territory — managing demand that exceeds supply — Eli Lilly · 41 upvotes
• Genentech oncology interview breakdown — 5 rounds — Roche / Genentech · 41 upvotes
• GSK respiratory — Nucala vs Fasenra still going strong — GlaxoSmithKline (GSK) · 40 upvotes
• BMS CV reps — are you hearing anything about Q3 headcount decisions? — Bristol Myers Squibb · 38 upvotes
• AbbVie Skyrizi launch in IBD — one year in — AbbVie · 38 upvotes
• Caplyta MDD indication changing my territory completely — Intra-Cellular Therapies · 35 upvotes
• Pfizer oncology comp — negotiation tips from someone who pushed back — Pfizer · 30 upvotes
• Dupixent access in atopic derm — my honest 2026 update — Sanofi · 27 upvotes
• Gilead HIV interview — rejected after 4 rounds — Gilead Sciences · 27 upvotes
• Keytruda expansion — great for science, brutal for reps — Merck (MSD) · 26 upvotes
• AbbVie culture from someone who stayed 8 years — AbbVie · 25 upvotes
• BMS layoffs round 2 — southeast getting cut — Bristol Myers Squibb · 22 upvotes
• Dupixent access still best in class — formulary wins coming — Regeneron · 22 upvotes
• Biktarvy still sells itself — but what happens when generics hit — Gilead Sciences · 20 upvotes
• Tecentriq pullback — what does it mean for our team — Roche / Genentech · 20 upvotes
• Corcept is eating our lunch in Cushing's — anyone else? — Neurocrine Biosciences · 18 upvotes
• Jakafi biosimilar threat — what leadership is telling us vs reality — Incyte · 17 upvotes

All Posts · News